共 50 条
- [41] HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patientsEJHAEM, 2024, 5 (04): : 815 - 819Minnema, Monique C.Nasserinejad, KazemHegenbart, UteYpma, Paula F.Wu, Ka LungKersten, Marie JoseCroockewit, SandraZweegman, SonjaTick, LidwineBroijl, AnnemiekKoene, HarryBos, Gerard M. J.Sonneveld, PieterSchonland, Stefan O.
- [42] Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaBMC Cancer, 19Hans SalwenderUta BertschKatja WeiselJan DuerigChristina KunzAxel BennerIgor W. BlauMarc Steffen RaabJens HillengassDirk HoseStefanie HuhnMichael HundemerMindaugas AndrulisAnna JauchAndrea Seidel-GlaetzerHans-Walter LindemannManfred HenselStefan FronhoffsUwe MartensTimon HansenMohammed WattadUllrich GraevenMarkus MunderRoland FenkMathias HaenelChristof ScheidHartmut Goldschmidt
- [43] Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaBMC CANCER, 2019, 19 (1)Salwender, HansBertsch, UtaWeisel, KatjaDuerig, JanKunz, ChristinaBenner, AxelBlau, Igor W.Raab, Marc SteffenHillengass, JensHose, DirkHuhn, StefanieHundemer, MichaelAndrulis, MindaugasJauch, AnnaSeidel-Glaetzer, AndreaLindemann, Hans-WalterHensel, ManfredFronhoffs, StefanMartens, UweHansen, TimonWattad, MohammedGraeven, UllrichMunder, MarkusFenk, RolandHaenel, MathiasScheid, ChristofGoldschmidt, Hartmut
- [45] Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (08): : 533 - 540Mina, RobertoPetrucci, Maria TeresaCorradini, PaoloSpada, StefanoPatriarca, FrancescaCerrato, ChiaraDe Paoli, LorenzoPescosta, NorbertRia, RobertoMalfitano, AlessandraMusto, PellegrinoBaldini, LucaGuglielmelli, TommasinaGamberi, BarbaraMannina, DonatoBenevolo, GiuliaZambello, RenatoFalcone, Antonietta PiaPalumbo, AntonioNagler, ArnonCalafiore, ValeriaHajek, RomanSpencer, AndrewBoccadoro, MarioBringhen, Sara
- [46] Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (07) : 634 - +Palumbo, AntonioBringhen, SaraLarocca, AlessandraRossi, DavideDi Raimondo, FrancescoMagarotto, ValeriaPatriarca, FrancescaLevi, AnnaBenevolo, GiuliaVincelli, Iolanda DonatellaGrasso, MariellaFranceschini, LucaGottardi, DanielaZambello, RenatoMontefusco, VittorioFalcone, Antonietta PiaOmede, PaolaMarasca, RobertoMorabito, FortunatoMina, RobertoGuglielmelli, TommasinaNozzoli, ChiaraPassera, RobertoGaidano, GianlucaOffidani, MassimoRia, RobertoPetrucci, Maria TeresaMusto, PellegrinoBoccadoro, MarioCavo, Michele
- [47] GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance - Final Analysis On Induction TherapyBLOOD, 2013, 122 (21)Goldschmidt, HartmutDuerig, JanBertsch, UtaKunz, ChristinaHielscher, ThomasHaenel, MathiasBlau, Igor WolfgangHose, DirkJauch, AnnaSchurich, BaerbelNeben, KaiSeckinger, AnjaHuegle-Doerr, BarbaraMerz, MaximilianMunder, MarkusLindemann, WalterZeis, MatthiasGerecke, ChristianSchmidt-Wolf, Ingo G. H.Weisel, KatjaScheid, ChristofSalwender, Hans
- [48] Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-upJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Jakubowiak, Andrzej J.Dytfeld, DominikGriffith, Kent A.Jasielec, JagodaMcDonnell, KathrynLebovic, DanielVesole, David H.Jagannath, SundarChottiner, Elaine G.Anderson, Tara B.Detweiler-Short, KristenStockerl-Goldstein, KeithAhmed, Asra Z.Jobkar, Terri L.Durecki, Diane E.Mietzel, Melissa A.Couriel, Daniel R.Vij, RaviKaminski, Mark Stefan
- [49] DO WE STILL NEED THE ALKYLATORS AS PART OF THE UPFRONT-TREATMENT OF ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS? UPDATED FOLLOW-UP OF GEM2005MAS65 SPANISH TRIAL COMPARING VMP VS VTP AS INDUCTIONHAEMATOLOGICA, 2014, 99 : 221 - 221Mateos, M. V.Oriol, A.Martinez-Lopez, J.Teruel, A. I.Lopez de la Guia, A.Blanchard, M. J.Bengoechea, E.Perez, M.Diaz-Mediavilla, J.Palomera, L.de Arriba, F.Gonzalez, Y.Hernandez, J. M.Granell, M.Bello, J. L.Bargay, J.Penalver, F. J.Martin, M. L.Paiva, B.Montalban, M. A.Blade, J.Lahuerta, J. J.San Miguel, J.
- [50] Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialLANCET ONCOLOGY, 2024, 25 (08): : 1003 - 1014Moreau, PhilippeHulin, CyrillePerrot, AuroreArnulf, BertrandBelhadj, KarimBenboubker, LotfiZweegman, SonjaCaillon, HeleneCaillot, DenisAvet-Loiseau, HerveDelforge, MichelDejoie, ThomasFacon, ThierrySonntag, CecileFontan, JeanMohty, MohamadJie, Kon-SiongKarlin, LionelKuhnowski, FrederiqueLambert, JeromeLeleu, XavierMacro, MargaretOrsini-Piocelle, FrederiqueRoussel, MurielleColella, Jean Marc Schiano devan de Donk, Niels W. C. J.Wuilleme, SorayaBroijl, AnnemiekTouzeau, CyrilleTiab, MouradMarolleau, Jean-PierreMeuleman, NathalieVekemans, Marie-ChristianeWesterman, MatthijsKlein, Saskia K.Levin, Mark-DavidOffner, FritzEscoffre-Barbe, MartineEveillard, Jean-RichardGaridi, RedaHua, WinnieWang, JianpingTuozzo, Albade Boer, CarlaRowe, MelissaVanquickelberghe, VeroniqueCarson, RobinVermeulen, JessicaCorre, JillSonneveld, Pieter